ANI Pharmaceuticals, Inc. $ANIP Shares Purchased by Caitong International Asset Management Co. Ltd

Caitong International Asset Management Co. Ltd lifted its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 4,636.4% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 521 shares of the specialty pharmaceutical company’s stock after purchasing an additional 510 shares during the quarter. Caitong International Asset Management Co. Ltd’s holdings in ANI Pharmaceuticals were worth $34,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. Hohimer Wealth Management LLC boosted its position in shares of ANI Pharmaceuticals by 5.2% in the 1st quarter. Hohimer Wealth Management LLC now owns 4,989 shares of the specialty pharmaceutical company’s stock valued at $334,000 after purchasing an additional 247 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of ANI Pharmaceuticals by 0.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company’s stock valued at $3,235,000 after purchasing an additional 423 shares during the period. Advisors Asset Management Inc. acquired a new stake in shares of ANI Pharmaceuticals in the 1st quarter valued at about $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of ANI Pharmaceuticals by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company’s stock valued at $736,000 after purchasing an additional 470 shares during the period. Finally, KLP Kapitalforvaltning AS boosted its position in shares of ANI Pharmaceuticals by 23.3% in the 2nd quarter. KLP Kapitalforvaltning AS now owns 3,700 shares of the specialty pharmaceutical company’s stock valued at $241,000 after purchasing an additional 700 shares during the period. 76.05% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, CFO Stephen P. Carey sold 50,000 shares of the stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $86.07, for a total transaction of $4,303,500.00. Following the completion of the transaction, the chief financial officer directly owned 180,863 shares of the company’s stock, valued at approximately $15,566,878.41. This represents a 21.66% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Jeanne Thoma sold 21,540 shares of the firm’s stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $89.15, for a total value of $1,920,291.00. Following the completion of the transaction, the director directly owned 23,405 shares of the company’s stock, valued at $2,086,555.75. The trade was a 47.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 413,830 shares of company stock worth $36,505,378. 12.70% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ANIP. Truist Financial upped their target price on ANI Pharmaceuticals from $77.00 to $90.00 and gave the company a “hold” rating in a research report on Thursday, October 9th. HC Wainwright increased their price objective on ANI Pharmaceuticals from $93.00 to $121.00 and gave the stock a “buy” rating in a research report on Wednesday, September 17th. Piper Sandler reaffirmed an “overweight” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. Zacks Research raised ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 21st. Finally, Weiss Ratings raised ANI Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $99.14.

ANI Pharmaceuticals Stock Performance

Shares of ANIP stock opened at $94.24 on Monday. The company has a market cap of $2.05 billion, a price-to-earnings ratio of -122.39 and a beta of 0.58. The stock has a 50 day simple moving average of $93.38 and a 200-day simple moving average of $75.91. ANI Pharmaceuticals, Inc. has a 12-month low of $52.50 and a 12-month high of $99.50. The company has a current ratio of 2.54, a quick ratio of 1.96 and a debt-to-equity ratio of 1.39.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Thursday, June 8th. The specialty pharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter. The business had revenue of $64.48 million for the quarter. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%. On average, equities analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.